+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.

Age: 18Years +All GendersPhase 3
301 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations
C

Actively Recruiting

Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.

Age: 18Years - 100YearsAll GendersPhase 3
424 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.

Age: 18Years +All GendersPhase 3
288 locations
S

Actively Recruiting

Researchers are evaluating how well amivantamab combined with lazertinib or with chemotherapy works in treating participants with epidermal growth factor receptor mutated EGFRm non-small cell lung cancer NSCLC, a common type of lung cancer. This Phase 2b study focuses on patients whose NSCLC is locally advanced or metastatic and who have specific EGFR mutations. The study aims to assess antitumor activity and treatment effects over time. Participants are assigned to one of two treatment groups. One group receives subcutaneous amivantamab combined with oral lazertinib in 28-day cycles, and the other group receives subcutaneous amivantamab combined with intravenous platinum-based chemotherapy carboplatin and pemetrexed in 21-day cycles. Treatment continues until disease progression, withdrawal, death, or investigator decision. The study is open-label and non-randomized, consisting of two parallel cohorts. During the study, participants will undergo regular assessments to monitor tumor response and safety. Key measures include progression-free survival tracked for up to 4 years and 6 months, along with evaluations of adverse events, overall survival, response rates, and duration of response. Researchers will also monitor dose changes and specific side effects such as venous thromboembolic events and dermatologic reactions. Participation may last several years depending on individual treatment and disease course.

Age: 18Years +All GendersPhase 2
205 locations
P

Actively Recruiting

Researchers are investigating the efficacy of divarasib compared with the investigators choice of immunotherapy pembrolizumab or nivolumab or observation in adults with resected Stage II-IIIB non-small cell lung cancer NSCLC that tests positive for the KRAS G12C mutation. This study focuses on participants who have not achieved a complete pathological response following neoadjuvant chemoimmunotherapy, regardless of tumor PD-L1 status. The trial aims to assess disease-free survival and overall survival in this patient group. Participants will be randomly assigned to one of two groups. One group will receive divarasib orally once daily for up to 52 cycles, each cycle lasting 21 days. The other group will receive either pembrolizumab or nivolumab immunotherapy, administered according to prior treatment type, or will be observed without study treatment. Pembrolizumab is given as an intravenous infusion every three weeks or a subcutaneous injection every three weeks for up to 13 cycles. Nivolumab is given as an intravenous infusion or subcutaneous injection every four weeks for up to 13 cycles. Observation participants will not receive any study treatment. Throughout the study, participants will be monitored for disease recurrence or death for up to approximately five years to assess disease-free survival. Additional outcomes include overall survival for up to eight years, adverse events tracking up to 60 days after treatment ends, and disease-free survival rates at two and three years. Participants will undergo regular evaluations to monitor their health status and study outcomes. The total duration of participation may extend up to eight years from randomization.

Age: 18Years +All GendersPhase 3
46 locations
F

Actively Recruiting

Researchers are evaluating the safety and effectiveness of osimertinib tablets combined with Datopotamab Deruxtecan intravenous infusion compared to osimertinib alone as a first treatment for participants with locally advanced or metastatic non-small cell lung cancer NSCLC that has specific EGFR mutations Ex19del andor L858R. This global Phase III, open-label, randomized study includes participants who have not received prior therapy for advanced disease, aiming to assess treatment benefits over approximately 8 years. Participants are randomly assigned to one of two groups one group receives osimertinib 80 mg orally once daily plus Datopotamab Deruxtecan 6 mgkg by intravenous infusion every 3 weeks, while the other group receives osimertinib 80 mg orally once daily alone. Treatment continues until disease progression, unacceptable side effects, or other discontinuation reasons. Visits occur every 3 weeks during treatment, with additional assessments every 6 weeks from cycle 7 to cycle 17, then every 12 weeks for those on osimertinib alone or after discontinuing Datopotamab Deruxtecan. Participants will attend regular visits for treatment administration and assessments, including scans and laboratory tests to monitor disease status and safety. Researchers will measure progression-free survival, overall survival, response rates, and the impact on brain metastases over the study period. Pharmacokinetics and immunogenicity of the drugs will also be evaluated. The study includes continuous safety monitoring and may last up to 8 years, with visits and evaluations scheduled throughout treatment and follow-up.

Age: 18Years +All GendersPhase 3
167 locations